JP2023552180A5 - - Google Patents

Info

Publication number
JP2023552180A5
JP2023552180A5 JP2023532682A JP2023532682A JP2023552180A5 JP 2023552180 A5 JP2023552180 A5 JP 2023552180A5 JP 2023532682 A JP2023532682 A JP 2023532682A JP 2023532682 A JP2023532682 A JP 2023532682A JP 2023552180 A5 JP2023552180 A5 JP 2023552180A5
Authority
JP
Japan
Prior art keywords
ascorbic acid
pharmaceutical composition
composition according
sodium ascorbate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552180A (ja
Filing date
Publication date
Priority claimed from PCT/EP2020/083363 external-priority patent/WO2022111800A1/en
Application filed filed Critical
Publication of JP2023552180A publication Critical patent/JP2023552180A/ja
Publication of JP2023552180A5 publication Critical patent/JP2023552180A5/ja
Pending legal-status Critical Current

Links

JP2023532682A 2020-11-25 2021-11-24 放射性核種錯体のための安定な製剤 Pending JP2023552180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2020/083363 2020-11-25
PCT/EP2020/083363 WO2022111800A1 (en) 2020-11-25 2020-11-25 Stable formulations for radionuclide complexes
PCT/EP2021/082812 WO2022112323A1 (en) 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes

Publications (2)

Publication Number Publication Date
JP2023552180A JP2023552180A (ja) 2023-12-14
JP2023552180A5 true JP2023552180A5 (https=) 2024-12-04

Family

ID=73598128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532682A Pending JP2023552180A (ja) 2020-11-25 2021-11-24 放射性核種錯体のための安定な製剤

Country Status (8)

Country Link
US (2) US20240374732A1 (https=)
EP (1) EP4251213A1 (https=)
JP (1) JP2023552180A (https=)
KR (1) KR20230134472A (https=)
CN (1) CN116806144A (https=)
AU (1) AU2021388832A1 (https=)
CA (1) CA3171753A1 (https=)
WO (2) WO2022111800A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
US20250099634A1 (en) 2023-09-25 2025-03-27 Novartis Ag Method of treating cancer
WO2025255398A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
US12343409B1 (en) * 2024-06-05 2025-07-01 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
CN120733077B (zh) * 2025-09-01 2025-12-05 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
PL2970345T3 (pl) 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
US10756278B2 (en) 2017-07-18 2020-08-25 Purdue Research Foundation In situ thermal control of langmuir-schaefer transfer
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2023552180A5 (https=)
CN102458396B (zh) 使用抗坏血酸稳定化放射性药物组合物
JP2025111424A5 (https=)
US20090155167A1 (en) Automated method
AU2024227297A1 (en) Methods for radiolabeling PSMA binding ligands and their kits
TW201726586A (zh) 同位素製備法
JP2015516457A (ja) 放射性医薬品の製造用キット及び製造方法
RU2568888C1 (ru) СПОСОБ И СОСТАВ ДЛЯ ПОЛУЧЕНИЯ РЕАГЕНТА ДЛЯ РАДИОНУКЛИДНОЙ ДИАГНОСТИКИ НА ОСНОВЕ МЕЧЕННОЙ ТЕХНЕЦИЕМ-99m 5-ТИО-D-ГЛЮКОЗЫ
JP4345954B2 (ja) 放射性医薬品の安定化剤
WO2023202730A2 (zh) 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途
JP4242465B2 (ja) 放射線防護剤
CN117500773A (zh) 在标记步骤期间制备具有低水含量的[18f]放射性标记化合物的方法
RU2846977C1 (ru) Способы мечения радиоактивными изотопами psma-связывающих лигандов и наборы для их осуществления
AU2010237040B9 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1245645B (zh) 使用抗坏血酸稳定化放射性药物组合物
HK1167344A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1170672B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1170672A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid